In light of the recently presented and overwhelmingly positive findings of the SUMMIT MAX randomised controlled trial (RCT), leading study investigator Ajit Puri (Worcester, USA) discusses the “paradigm shift” he now envisions for interventional stroke care.
Speaking to NeuroNews at the 2025 Society of NeuroInterventional Surgery (SNIS) annual meeting (14–18 July, Nashville, USA), Puri describes the HiPoint Reperfusion System (Route 92 Medical) evaluated in SUMMIT MAX as a “phenomenal tool”, outlining his firsthand experiences with the technology as well as digging down into some of the key data from this landmark RCT in the neurovascular space.
This video is sponsored by Route 92 Medical.
